These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32676952)

  • 1. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions.
    Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E
    Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoemulsions containing amphotericin b and paromomycin for the treatment of cutaneous leishmaniasis.
    Cunha NFC; de Siqueira LBO; Garcia AR; Rodrigues IA; Matos APDS; Júnior ER; Monteiro MSSB
    Acta Trop; 2024 Jun; 254():107189. PubMed ID: 38522630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
    Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
    Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
    Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
    Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions.
    Carvalheiro M; Vieira J; Faria-Silva C; Marto J; Simões S
    Drug Deliv Transl Res; 2021 Apr; 11(2):717-728. PubMed ID: 33534106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of
    Anjum A; Shabbir K; Din FU; Shafique S; Zaidi SS; Almari AH; Alqahtani T; Maryiam A; Moneeb Khan M; Al Fatease A; Bashir S; Khan GM
    Drug Deliv; 2023 Dec; 30(1):2173335. PubMed ID: 36722301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
    Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes.
    Prajapat VM; Aalhate M; Sriram A; Mahajan S; Maji I; Gupta U; Kumari D; Singh K; Kalia NP; Dua K; Singh SK; Singh PK
    Parasitol Int; 2024 Jun; 100():102848. PubMed ID: 38159836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
    Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
    Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
    Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
    Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity.
    Berenguer D; Alcover MM; Sessa M; Halbaut L; Guillén C; Boix-Montañés A; Fisa R; Calpena-Campmany AC; Riera C; Sosa L
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32059430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models.
    Riaz A; Hendricks S; Elbrink K; Guy C; Maes L; Ahmed N; Kiekens F; Khan GM
    AAPS PharmSciTech; 2020 Jul; 21(5):185. PubMed ID: 32632542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
    de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
    Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol improves stability of amphotericin B nanoemulsion: promising use in the treatment of cutaneous leishmaniasis.
    Mansur-Alves I; Lima BLF; Santos TT; Araújo NF; Frézard F; Islam A; de Barros AL; Dos Santos DC; Fernandes C; Ferreira LA; Aguiar MM
    Nanomedicine (Lond); 2022 Aug; 17(18):1237-1251. PubMed ID: 36189757
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
    Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
    Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
    Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis.
    Silva-Carvalho R; Fidalgo J; Melo KR; Queiroz MF; Leal S; Rocha HA; Cruz T; Parpot P; Tomás AM; Gama M
    Int J Biol Macromol; 2020 Jun; 153():276-288. PubMed ID: 32145228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases.
    Fernández-García R; Statts L; de Jesus JA; Dea-Ayuela MA; Bautista L; Simão R; Bolás-Fernández F; Ballesteros MP; Laurenti MD; Passero LFD; Lalatsa A; Serrano DR
    ACS Infect Dis; 2020 Oct; 6(10):2647-2660. PubMed ID: 32810398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.